Group 1 - The core point of the article highlights the recent performance of Hualu Bio, which saw a 5.07% increase in stock price, reaching 21.54 CNY per share, with a trading volume of 1.03 billion CNY and a turnover rate of 5.16%, resulting in a total market capitalization of 2.641 billion CNY [1] - Hualu Bio, established on June 8, 2010, and listed on April 12, 2021, specializes in the research, industrial cultivation, and sales of edible mushrooms, with its main revenue sources being enoki mushrooms (70.73%) and king oyster mushrooms (29.27%) [1] Group 2 - From the perspective of fund holdings, Huatai-PineBridge Fund has a significant position in Hualu Bio, with its Huatai-PineBridge Quantitative Alpha A fund holding 90,400 shares, accounting for 0.5% of the fund's net value, making it the fifth-largest holding [2] - The Huatai-PineBridge Quantitative Alpha A fund, established on September 26, 2017, has a current size of 203 million CNY, with a year-to-date return of 5.9% and a one-year return of 39.99%, ranking 2766 out of 8836 and 3496 out of 8091 respectively [2] - The fund managers, Sheng Hao and Kong Lingye, have tenures of 10 years and 3 years respectively, with Sheng managing assets totaling 4.417 billion CNY and achieving a best return of 138.1% during his tenure [2]
华绿生物股价涨5.07%，华泰柏瑞基金旗下1只基金重仓，持有9.04万股浮盈赚取9.4万元